

Scenario: Post Ictal

Setting: ED Resus

Clinical Focus: Management of patient with reduced conscious level

Situational Factors: limited history

Learning Objectives:

• A-E assessment

Use of simple airway adjuncts

Management of Seizures

Stage/ Design/ Props/ Technical Setup

SimMan, Resus Kit, ?Medical alert bracelet (epilepsy), Phenytoin prescribing tool and guideline for seizure management

Briefing to Participants: Scene

Red Call - 2 minutes. 26 year old known epileptic has had a witnessed seizure. Now post ictal GCS E2 V3 M4 (9)

Presentation	Expected Response	Actors Notes
		Patient will moan and snore
Examination: A: Snoring/ obstructing airway B: Bilat air ent Sats 93 (air) C: HR 92 Bp 115/86 D: GCS e2 v3 m4 (9), Pearl E: Incontinent of urine, no rashes or fever	A-E assessment Basic airway maneuvers and adjuncts with O2 Checks BM IV access and bloods	
Progress Improves: Sats improve Has further seizure	Terminates with diazepam	Will need to prompt is fitting by faculty - give verbal prompt rather than making SimMan move
Progress Deteriorates: Sats deterioriate Further seizures - not terminating with benzos	Senior Input +/- ITU Phenytoin	Will need to prompt is fitting by faculty - give verbal prompt rather than making SimMan move
Debrief	Clinical	CRM
	Management of seizures Basic Airway management	When to call for help.



EMERGENCY DEPT ATTENDANCE RECORD

University Hospitals Of LEICESTER NHS Trust

Printed Copy No. 1

Leicester Royal Infirmary UHL Trust

LEICESTER



PATIENT IDENTIFIER	TRIAGE
Hospital No NHS No	ED Arrival
Last Name Malcolm	Triage Assessment
Forename Grand	Complaint
Date Of Birth 25/12/1990 Age: 26	Triage Nurse
Sex M	Nurse Assessment
Ethnic Category	
Address	
(Home)	
(Work)	
(Mobile)	
Occ/School	
Interpreter Required No	
Language HOME - OWN	
NEXT OF KIN/EMERGENCY CONTACT	1
Name Arnold Barry Sense	Triage Category
Relationship Partner	Thage Category
Address	CLINICAL ALERTS/ALLERGIES
, idd oss	Allergies
	Allergies
(Harra)	Clinical Alert
(Home)	
(Work) Emergency Contact	ATTENDANCE HISTORY
Thougardy contact	Date Discharge Diagnosis
REGISTERED GP	15/8/2015 - Seizure
Name Dr J. Dorian	07/3/2015 - Seizure
Surgery Sacred Heart	14/5/2014 - Seizure
Medical Practice	27/7/2013 - Seizure
Triculour Fractice	
- The state of the	
	1



VBG

PCO ₂ 6.5 kPa [4.27 - 6.40 PO ₂ 9.5 kPa () [11.07 - 14.40 PO ₂ 9.5 kPa () [11.07 - 14.40 PO ₂ 17.2 mmol/L Na* 137 mmol/L K* 3.9 mmol/L [3.50 - 5.10 PO ₂ 1.5 mmol/L [1.150 - 1.330 PO ₂ PO ₃ PO ₄ PO ₅ PO						-		Roche		
Serial number : 19241 Instrument ID : A&E 1 Operator ID : blood			Ma	Measurement report						
Instrument ID : A&E 1			IVIC	weasurement report						
Pat. ID Last name First name First name Sim Blood type FIO2 PH 7.33 (-) PCO2 6.5 kPa PO2 9.5 kPa () BE -7.7 mmol/L cHCO3 17.2 mmol/L Na* 137 mmol/L Ca²* 1.5 mmol/L Cb* Ca²* 1.5 mmol/L Cb* Ca²* 1.5 mmol/L Cb* Cb* Cb* Cb* Cb* Cb* Cb* Cb* Cb* Cb			Ir	Instrument ID: A&E 1						
Last name First name Sim Blood type Venous FIO ₂ 0.21 PH 7.33 (-) [7.350 - 7.450 PCO ₂ 6.5 kPa [4.27 - 6.40 PO ₂ 9.5 kPa () [11.07 - 14.40 BE -7.7 mmol/L cHCO ₃ 17.2 mmol/L Na* 137 mmol/L CA2* 1.5 mmol/L CC 106 mmol/L Glu 4.2 mmol/L Lac 4.7 mmol/L Urea 5.6 mmol/L Vena 5.6 mmol/L AG 17 mmol/L Osm 282 mosm/kg Hct 45 % () [36.0 - 53.0 Hct(c) 45 % The transfer of the tran			St	. Elsewhere l	Emergen	cy Dept				
Blood type				S1234567						
Blood type										
FIO2 0.21 PH 7.33 (-) [7.350 - 7.450 PCO2 6.5 kPa [4.27 - 6.40 PO2 9.5 kPa () [11.07 - 14.40 PCO3 17.2 mmol/L CHCO3 17.2 mmol/L Na* 137 mmol/L [3.50 - 5.10 Ca²* 1.5 mmol/L [98.0 - 107.0 CG²* 1.5 mmol/L [98.0 - 107.0 CG] Glu 4.2 mmol/L [3.5 - 5.3 CG] Lac 4.7 mmol/L [0.4 - 0.8 CG] Lac 4.7 mmol/L [0.4 - 0.8 CG] Lac 4.7 mmol/L [0.4 - 0.8 CG] Lac 4.7 mmol/L [1.150 - 178.0 CG] Hct 45 % () [36.0 - 53.0 CG] Hct 45 % () [36.0 - 53.0 CG] Hct 45 % [0.0 - 3.0 CG] MetHb 1.4 % [0.0 - 1.5 CG] MetHb 1.4 % [0.0 - 1.5 CG] MetHb 1.4 % [0.0 - 1.5 CG] MetHb 1.4 % [0.0 - 2.5 CG] O ₂ Hb 15 % [94.0 - 98.0 CG]	٢	irst name								
PH 7.33 (-) [7.350 - 7.450 PCO2 6.5 kPa [4.27 - 6.40 PO2 9.5 kPa () [11.07 - 14.40 PCO3 17.2 mmol/L Na* 137 mmol/L CHCO3 17.2 mmol/L Na* 137 mmol/L Ca2* 1.5 mmol/L [3.50 - 5.10 Ca2* 1.5 mmol/L [98.0 - 107.0	-	llood tune	V	enous						
PCO2 6.5 kPa [4.27 - 6.40 PO2 9.5 kPa () [11.07 - 14.40 PO2 9.5 kPa () [11.07 - 14.40 PO2 PO2 9.5 kPa () [11.07 - 14.40 PO2										
PCO2 6.5 kPa [4.27 - 6.40 PO2 9.5 kPa () [11.07 - 14.40 PO2 9.5 kPa () [11.07 - 14.40 PO2 PO2 9.5 kPa () [11.07 - 14.40 PO2		Н	7.33	(-)		1	7.350 -	7.450		
PO2 9.5 kPa () [11.07 - 14.40 BE						1	4.27 -	6.40		
CHCO₃ 17.2 mmol/L Na* 137 mmol/L [136.0 - 145.0 K* 3.9 mmol/L [3.50 - 5.10 Ca²* 1.5 mmol/L [1.150 - 1.330 Cl⁻ 106 mmol/L [98.0 - 107.0 Glu 4.2 mmol/L [3.5 - 5.3 Lac 4.7 mmol/L [0.4 - 0.8 Urea 5.6 mmol/L [2.5 - 6.4 AG 17 mmol/L [2.5 - 6.4 AG 282 mOsm/kg Hct 45 % () [36.0 - 53.0 thb 132 g/L [115.0 - 178.0 SO₂ 76 % [94.0 - 98.0 MetHb 1.4 % [0.0 - 1.5 MetHb 1.4 % [0.0 - 1.5 Hhb 2.5 % [0.0 - 2.5 O₂Hb 15 % [94.0 - 98.0 O₂Hb 15			9.5		SV.]	11.07 -	14.40		
CHCO₃ 17.2 mmol/L [136.0 - 145.0 Na* 137 mmol/L [3.50 - 5.10 K* 3.9 mmol/L [1.150 - 1.330 Ca²* 1.5 mmol/L [1.150 - 1.330 Cl* 106 mmol/L [98.0 - 107.0 Glu 4.2 mmol/L [3.5 - 5.3 Lac 4.7 mmol/L [0.4 - 0.8 Urea 5.6 mmol/L [2.5 - 6.4 AG 17 mmol/L [2.5 - 6.4 Osm 282 mOsm/kg Hct 45 % () [36.0 - 53.0 Hct(c) 45 % [115.0 - 178.0 SO₂ 76 % [94.0 - 98.0 COHb 0.5 % [0.0 - 3.0 MetHb 1.4 % [0.0 - 1.5 HHb 2.5 % [0.0 - 2.5 O₃Hb 15 % [94.0 - 98.0			127.22							
Na* 137 mmol/L [136.0 - 145.0 K* 3.9 mmol/L [3.50 - 5.10 Ca²* 1.5 mmol/L [1.150 - 1.330 Cl* 106 mmol/L [98.0 - 107.0 Glu 4.2 mmol/L [3.5 - 5.3 Lac 4.7 mmol/L [0.4 - 0.8 Urea 5.6 mmol/L [2.5 - 6.4 AG 17 mmol/L [2.5 - 6.4 Osm 282 mOsm/kg Hct 45 % () [36.0 - 53.0 Hct(c) 45 % [15.0 - 178.0 SO₂ 76 % [94.0 - 98.0 COHb 0.5 % [0.0 - 3.0 MetHb 1.4 % [0.0 - 1.9 HHb 2.5 % [0.0 - 2.0 O₂Hb 15 % [94.0 - 98.0								**		
K* 3.9 mmol/L [3.50 - 5.10 Ca²* 1.5 mmol/L [1.150 - 1.330 Cl* 106 mmol/L [98.0 - 107.0 Glu 4.2 mmol/L [98.0 - 107.0 Lac 4.7 mmol/L [0.4 - 0.8 Urea 5.6 mmol/L [0.4 - 0.8 Urea 5.6 mmol/L [2.5 - 6.4 AG 17 mmol/L [2.5 - 6.4 Osm 282 mOsm/kg Hct 45 % () [36.0 - 53.0 Hct(c) 45 % Thet(c) 45 % Image: Company of the company of th	0	HCO3	17.2	mmol/L						
Ca ³⁺ 1.5 mmol/L [1.150 - 1.330 Cl ⁻ 106 mmol/L [98.0 - 107.0 Cl ⁻ 106 mmol/L [98.0 - 107.0 Cl ⁻ 107.0 Cl ⁻ 107.0 Cl ⁻ 108.0 - 107.0 Cl ⁻ 108.0 - 107.0 Cl ⁻ 108.0			137			[145.0		
Cir 106 mmol/L [98.0 - 107.0] Glu 4.2 mmol/L [3.5 - 5.3] Lac 4.7 mmol/L [0.4 - 0.8] Urea 5.6 mmol/L [2.5 - 6.4] AG 17 mmol/L Osm 282 mOsm/kg Hct 45 % () [36.0 - 53.0] Hct(c) 45 % tHb 132 g/L [115.0 - 178.0] SO ₂ 76 % [94.0 - 98.0] COHb 0.5 % [0.0 - 3.0] MetHb 1.4 % [0.0 - 1.0] HHb 2.5 % [0.0 - 2.0] O ₂ Hb 15 % [94.0 - 98.0]						1				
Glu 4.2 mmol/L [3.5 - 5.3 Lac 4.7 mmol/L [0.4 - 0.6 Lac 5.6 mmol/L [0.4 - 0.6 Lac 5.6 mmol/L [2.5 - 6.4 Lac 5.6 mmol/L] [36.0 - 53.6						1				
Lac 4.7 mmol/L [0.4 - 0.8 Local Lines	(CI	106	mmol/L		[98.0 -	107.0		
Urea 5.6 mmol/L [2.5 - 6.4 AG	(Glu	4.2	mmol/L		1		,5.3		
Urea 5.6 mmol/L [2.5 - 6.4 AG 17 mmol/L	l	Lac	4.7	mmol/L		1		0.8		
Osm 282 mOsm/kg Hct 45 % () [36.0 - 53.0 Hct(c) 45 % tHb 132 g/L [115.0 - 178.0 SO2 76 % [94.0 - 98.0 COHb 0.5 % [0.0 - 3.0 MetHb 1.4 % [0.0 - 1.0 HHb 2.5 % [0.0 - 2.0 O2Hb 15 % [94.0 - 98.0			5.6	mmol/L	*]	2.5 -	6.4		
Osm 282 mOsm/kg Hct 45 % () [36.0 - 53.0 Hct(c) 45 % tHb 132 g/L [115.0 - 178.0 SO2 76 % [94.0 - 98.0 COHb 0.5 % [0.0 - 3.0 MetHb 1.4 % [0.0 - 1.0 HHb 2.5 % [0.0 - 2.0 O2Hb 15 % [94.0 - 98.0		AG	17	mmol/L				2		
Hct(c) 45 % tHb 132 g/L [115.0 - 178.0 SO ₂ 76 % [94.0 - 98.0 COHb 0.5 % [0.0 - 3.0 MetHb 1.4 % [0.0 - 1.0 HHb 2.5 % [0.0 - 2.0 O ₂ Hb 15 % [94.0 - 98.0 SO ₂										
Hct(c) 45 % tHb 132 g/L [115.0 - 178.0 SO ₂ 76 % [94.0 - 98.0 COHb 0.5 % [0.0 - 3.0 MetHb 1.4 % [0.0 - 1.0 HHb 2.5 % [0.0 - 2.0 O ₂ Hb 15 % [94.0 - 98.0 SO ₂		Hct	45	% ()		1	36.0 -	53.0		
SO ₂ 76 % [94.0 - 98.0 COHb 0.5 % [0.0 - 3.0 MetHb 1.4 % [0.0 - 1.0 Hb 2.5 % [0.0 - 2.0 C ₂ Hb 15 % [94.0 - 98.0 COHb 15	1	Hct(c)	45	%		752				
SO ₂ 76 % [94.0 - 98.0 COHb 0.5 % [0.0 - 3.0 MetHb 1.4 % [0.0 - 1.0 Hb 2.5 % [0.0 - 2.0 C ₂ Hb 15 % [94.0 - 98.0 COHb 15		tHb	132	g/L]		178.0		
COHb 0.5 % [0.0 - 3.0 model] MetHb 1.4 % [0.0 - 1.0 model] HHb 2.5 % [0.0 - 2.0 model] O ₂ Hb 15 % [94.0 - 98.0 model]]		98.0		
HHb 2.5 % [0.0 - 2.5 %]			0.5	%		1		3.0		
O ₂ Hb 15 % . [94.0 - 98.0				%		1		1.5		
0,10		HHb]		2.9		
Billi Out of range (-) [51- 85		O ₂ Hb	15	%		1	94.0 -	98.0		
		Bili	Out of range)	1	51-	850		
* STEEL VERI										



Sample No.: \$1234567

Patient ID: Name:

Rack: Ward:

Tube:

12:34:35

Dr.: Birth:

Sex:

Comments:

Inst.ID:XS-800i^65614

WBC	12.7	[10^9/L]	
RBC	2.08	[10^12/L]	
HGB	132	[g/L]	
HCT	0.184	[Ratio]	
MCV	88.0	[fL]	
MCH	29.8	[pg]	
MCHC	339	[g/L]	
PLT	250	[10 ⁹ /L]	
RDW-SD	42.4	[fL]	
RDW-CV	14.0	[%]	
PDW	11.3	[fL]	
MPV	10.5	[fL]	
P-LCR	27.7	[%]	
PCT	0.18	[%]	
NEUT	5.2	[10 ⁹ /L]	65.5
LYMPH	2.75	[10 ⁹ /L]	15.6 *
MONO	1.58	[10 ⁹ /L]	9.0 *
EO	0.04	[10 ⁹ /L]	0.2 *
BASO	0.03	[10 ⁹ /L]	0.2

Actions required

- □ Normal
- ☐ Abnormal but no immediate danger
- ☐ Significantly abnormal results *patient in imminent danger*

document STAT actions taken

NPT samples processed by

MDT reculte



Infusion rate

LRI ED IV Phenytoin Preparation Aid: Patients >49kg

- This chart is intended for use in the Emergency Department (ED) as an adjunct to the following trust documents
 - IV monograph for phenytoin administration in adults (on Medusa)
 - Management of status epilepticus in adults
- Total loading dose when using tables below will be 17 18mg/kg (**NB**: Do not use this document if patient is already on Phenytoin and give Phenobarbitone 20 mg/kg or Phenytoin 9mg/kg instead)
- Importantly, patients weighing 112 kg or more should just receive the 112kg dose (i.e. never exceed 2000mg total dose)
- Drug is infused NEAT (dilution carries a risk of precipitation and is therefore not recommended by manufacturer)
- An in-line filter is not required using this method

Woight

- Run infusion via syringe driver; flush IV line generously with 0.9% saline before and afterwards (NB: Do not use glucose)
- · Continuous cardiac monitoring must be in place and NIBP must be measured frequently

Phenytoin dose

- Standard infusion rate (independent of patient weight or total dose) is 60mL/h (i.e. giving 50mg/min)
- Stop infusion if low BP or bradycardia observed; once resolved restart at 30mL/h (i.e. giving 25mg/min)

50 - 112 kg (NB: patients weighing > 112kg should just receive the 112kg dose)

Find required volume of **NEAT** Phenytoin in table below.

Do not dilute.

Each vial contains 250mg in 5mL (i.e. **1mg = 0.02mL**).

Draw up the exact amount in a 60mL syringe.

	weight	Phenyu	oin aose	infusion rate				
		(17 - 18	3 mg/kg)	Standard - 60mL/h (delivers 50mg/min)	Slow - 30mL/h (delivers 25mg/min)			
		Drug	Volume	Time infusion will	and the second of the second o			
	kg	mg	mL	(NB: this is just for	your information)			
	50 - 52	900	18	18	36			
	53 - 55	950	19	19	38			
	56 - 58	1000	20	20	40			
	59 - 61	1050	21	21	42			
	62 - 63	1100	22	22	44			
	64 - 66	1150	23	23	46			
	67 - 69	1200	24	24	48			
	70 - 72	1250	25	25	50			
	73 - 74	1300	26	26	52			
•	75 - 77	1350	27	27	54			
	78 - 80	1400	28	28	56			
	81 - 83	1450	29	29	58			
	84 - 86	1500	30	30	60			
	87 - 88	1550	31	31	62			
	89 - 91	1600	32	32	64			
	92 - 94	1650	33	33	66			
	95 - 97	1700	34	34	68			
	98 - 99	1750	35	35	70			
	100 - 102	1800	36	36	72			
	103 - 105	1850	37	37	74			
	106 - 108	1900	38	38	76			
	109 - 111	1950	39	39	78			
	112 and over	2000	40	40	80			

Example prescription for 76kg patient

PARENTERAL INFUSIONS												
	Infusion	Fluid	Additions to	nfusion						Sig	Signatures	
Date	Type/Strength	Vol.	Medicine	Dose	Route	Time to run or ml/hr	Prescriber	Fluid Batch No.	Start Time	Given by	Checked by	
28/12/09	50mg/mL	27mL	Phenytoin (neat)	1350mg	IV	60mL/h	Your Name					



Status Epilepticus

University Hospitals of Leicester NHS Trust NHS

Guidelines for Management of Acute Medical Emergencies

Status epilepticus is defined as more than 30 minutes of continuous seizure activity or two or more seizures without full recovery of consciousness between seizures.

Immediate management

- Secure the airway, administer oxygen and support respiration if necessary
- · Assess cardiovascular status
- Obtain intravenous access
- Check and record blood glucose administer IV 50 ml of 50% glucose if hypoglycaemic (use large vein – very irritant)
- Administer IV Pabrinex if there is evidence of alcoholism or malnutrition ¹ (one pair of ampoules in 100mls of either sodium chloride 0.9% or glucose 5% over 20 minutes – see Procedures for Intravenous Administration of Pabrinex)
- Take blood for FBC, U&E, LFTs, calcium, glucose, pretreatment antiepileptic drug levels and toxicological analysis if appropriate
- Administer bolus of IV lorazepam 4mg^{2,3} can be repeated after 10 min if necessary
- Administer IV phenytoin 18 mg/kg by slow IV infusion at a maximum rate of 50 mg/min with ECG monitoring ^{4,5} IV phenytoin may be infused over 1 hour in 100 mls normal saline but must not be mixed with IV dextrose (see Procedure for Administration of Intravenous Phenytoin).
- Assess cause is there evidence of meningism, raised intracranial pressure, focal neurological signs, evidence of drug abuse, recent head injury, alcoholism or hepatic failure? Try to obtain an accurate recent drug history. Early neurological referral is usually appropriate.

If seizures cease

Admit to ward – close observation should be maintained for 24 hours with regular medical reassessment

If seizures persist > 30 min after initiation of treatment

Contact ITU anaesthetist in order to proceed to anaesthesia with IV thiopentone and ventilation

Notes:

- When IV glucose is given there is a risk of precipitating Wernicke's encephalopathy unless IV thiamine (as Pabrinex) is also given to thiamine-deficient patients.
- ² If there is delay in securing IV access give IM midazolam 10 mg
- ³ IV Diazemuls 10 mg is an acceptable alternative but has a much shorter duration of action lorazepam is preferred
- Do not administer phenytoin if there is a known past history of hypersensitivity to phenytoin or there is a definite history of myoclonic epilepsy— IV sodium valproate is an alternative (loading dose 20 mg/kg)
- ⁵ If the patient is known to be taking phenytoin at presentation, give an initial loading dose of 9 mg/kg